藥品名稱
drug name | Bupropion HCl (Wellbutrin XL, 威克倦持續性藥效錠) 150 mg/tab |
| 藥檔狀態 | 使用中 |
成 份
Ingredient | Bupropion HCl |
| 單位含量 | 150 mg/tab |
| Dosage Forms | XL Tablet, extended release, as hydrochloride: 150 mg/tab (不建議剝半或磨粉(持續性釋放膜衣錠)) |
| 外觀描述 | 圓形 白色 口服/持續藥效錠 |
| Appearance | round white oral/XL tablet |
標 示
outward | GS 5FV 150 |
廠商名稱
Manufacturer | 荷商葛蘭素史克藥廠股份有限公司台灣分公司 |
製 造 商
Manufacturer | Bausch Health Companies Inc., CANADA |
字 號
Product ID | 衛署藥製字第025106號 |
藥理分類
Pharmacologic Category | Psychiatry/ Antidepressants/ Miscellaneous (Dopamine/Norepinephrine-Reuptake Inhibitor); Psychiatry/ Substance Dependent Therapy |
作用機轉
Mechanism of action | Weak inhibitor of the neuronal uptake of serotonin, norepinephrine, and dopamine, and does not inhibit monoamine oxidase
Bupropion是一種catecholamines的神經元回收之選擇性抑制劑，雖然bupropion和其他抗憂鬱劑一樣，作用機轉還不明，但一般認為這種作用是由noradrenergic及dopaminergic機轉所媒介。 |
| 用途/適應症 | 憂鬱症 |
| Use |
Treatment of major depressive disorder, including seasonal affective disorder (SAD); adjunct in smoking cessation
|
衛福部核准適用症狀
MOHW approved indications |
治療憂鬱症。
|
| Dose |
【Adults】:
Depression: Initial: 150 mg/day in the morning; may increase as early as day 4 of dosing to 300 mg/day; maximum dose: 450 mg/day
SAD: Initial: 150 mg/day in the morning; if tolerated, may increase after 1 week to 300 mg/day (Note: Prophylactic treatment should be reserved for those patients with frequent depressive episodes and/or significant impairment. Initiate treatment in the Autumn prior to symptom onset, and discontinue in early Spring with dose tapering to 150 mg/day for 2 weeks)
【Dosage Adjustment in Hepatic Impairment】:
Severe hepatic cirrhosis: 150 mg QOD
(1)起始治療：每日一次150 mg，晨間服用，若反應不充足的患者，可提高到每日一次300 mg。
(2)維持療法：憂鬱症之急性發作需要以抗憂鬱劑治療六個月或更久，現已顯示Bupropion (300 mg/日)於長期(長達一年)治療是有效的。
(3)肝功能不全之患者：肝功能不全之患者應小心使用。輕至中度肝硬化的患者在藥動學方面的差異性增大，應考慮降低給藥頻率;重度肝硬化的患者，劑量不可超過隔日服用150 mg。
(4)腎功能不全之患者：建議劑量為每日一次150 mg。
|
懷孕分級
Pregnancy Risk Factor |
FDA: C。
仿單:針對懷孕女性或計畫懷孕的女性，開立藥物的醫師必須衡量可能的替代治療選擇，並且只有在預期效益高於潛在風險時才應該開立Wellbutrin XL。
Lactation: Enters breast milk/not recommended
|
| 禁忌症 |
(1)對於Bupropion或製劑中其他任何一種成分過敏者。
(2)癲癇患者。
(3)突然停止使用酒精或鎮靜劑的患者。
(4)正在使用其他含Bupropion製劑之患者，因癲癇發作的發生率與劑量有關。
(5)目前或先前被診斷患有貪食症或神經性厭食症之患者。
(6)不可與單胺氧化敏抑制劑(MAOIs)同時使用，停用MAOIs之後，至少需間隔14天才可開始使用Bupropion。
|
| Contraindications |
Seizure disorder; anorexia/bulimia; use of MAO inhibitors within 14 days; patients undergoing abrupt discontinuation of ethanol or sedatives (including benzodiazepines); patients receiving other forms of bupropion
|
| 常見副作用 | 心搏過速，躁動，失眠 |
| Common adverse drug reactions | Fast heartbeat, agitation, sleepless. |
| Adverse Reactions |
＞10%:
Cardiovascular: Tachycardia (≦11%)
Central nervous system: Insomnia (11% to 40%), headache (25% to 34%), agitation (2% to 32%), dizziness
(6% to 22%)
Dermatologic: Diaphoresis (5% to 22%)
Endocrine & metabolic: Weight loss (14% to 23%)
Gastrointestinal: Xerostomia (10% to 28%), constipation (8% to 26%), nausea and vomiting (23%), nausea
(1% to 18%)
Neuromuscular & skeletal: Tremor (1% to 21%)
Ophthalmic: Blurred vision (3% to 15%)
Respiratory: Nasopharyngitis (13%), pharyngitis (3% to 13%), rhinitis (12%)
1% to 10%:
Cardiovascular: Palpitations (2% to 6%), cardiac arrhythmia (5%), chest pain (≦4%), flushing (≦4%),
hypertension (1% to 4%; may be severe), hypotension (3%)
Central nervous system: Lack of concentration (9%), confusion (≦8%), anxiety (3% to 8%), hostility (≦6%),
nervousness (4% to 5%), abnormal dreams (3% to 5%), sensory disturbance (4%), sleep disorder (4%),
migraine (≦4%), irritability (3%), memory impairment (≦3%), drowsiness (2% to 3%), pain (3%), akathisia
(≦2%), central nervous system stimulation (≦2%), paresthesia (≦2%), twitching (≦2%), dystonia (≧1%),
abnormality in thinking (1%), depression
Dermatologic: Skin rash (1% to 8%), pruritus (2% to 4%), xeroderma (2%), urticaria (1% to 2%)
Endocrine & metabolic: Weight gain (9%), menstrual disease (2% to 5%), decreased libido (≦3%), hot flash
(1% to 3%)
Gastrointestinal: Abdominal pain (2% to 9%), diarrhea (4% to 7%), flatulence (6%), anorexia (1% to 5%),
dysgeusia (2% to 4%), increased appetite (2% to 4%), vomiting (≧1% to 4%), dyspepsia (3%), oral mucosa
ulcer (2%), dysphagia (≦2%)
Genitourinary: Urinary frequency (≧1% to 5%), urinary urgency (≦2%), vaginal hemorrhage (≦2%), urinary
tract infection (≦1%)
Hypersensitivity: Hypersensitivity reaction (1%)
Infection: Infection (8% to 9%)
Neuromuscular & skeletal: Myalgia (2% to 6%), arthralgia (4% to 5%), weakness (4%), neck pain (2%),
arthritis (≦2%), dyskinesia (≧1%)
Otic: Tinnitus (1% to 6%), auditory disturbance (5%)
Renal: Polyuria (≦1%)
Respiratory: Upper respiratory infection (9%), sinusitis (2% to 5%), cough (2% to 4%), increased cough (2%
to 3%), epistaxis (2%), bronchitis (≦2%)
Miscellaneous: Accidental injury (2%), fever (1% to 2%)
Frequency not defined: Ophthalmic: Diplopia (≦3%)
|
監測
Monitoring |
Body weight; mental status for depression, suicidal ideation (especially at the beginning of therapy or when doses are increased or decreased), anxiety, social functioning, mania, panic attacks; blood pressure (baseline and periodically especially when used in conjunction with nicotine transdermal replacement); renal and hepatic function
When used for the treatment of ADHD, thoroughly evaluate for cardiovascular risk. Monitor heart rate, blood pressure, and consider obtaining ECG prior to initiation (Vetter 2008).
|
| 警語與注意事項 | 肝或腎功能不全者，應減少用藥次數。不可撥半磨粉。易潮解, 請使用前開封。藥錠外殼會隨糞便排出 |
| Warnings & precautions | DON`T crush or cut tablet. |
| 針劑溶解條件 |
|
| 針劑稀釋條件 |
|
| 針劑不相容性 |
|
| 針劑施打條件 |
|
| 針劑保存安定性 |
25℃下儲存。
|
最近修改日期時間
Updated | 10/13/2023 9:57:15 AM |
|
現用藥品
Available
|
停用藥品
Old item
|
|
衛福部仿單連結
DrugLabelingURL
|
二維條碼
QR code
|
|